- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00063635
Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) (TONIC)
27. august 2012 oppdatert av: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)
The purpose of this study is to determine if therapeutic modification of insulin resistance or oxidative stress leads to improvement in serum or histologic indicators of liver injury or quality of life.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
173
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
California
-
San Diego, California, Forente stater, 92103
- University of California, San Diego
-
San Francisco, California, Forente stater, 94143
- University of California, San Francisco
-
-
District of Columbia
-
Washington, District of Columbia, Forente stater, 20010
- Children's National Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Indiana University
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21205
- Johns Hopkins University
-
-
Missouri
-
St. Louis, Missouri, Forente stater, 63110
- St. Louis University
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44109
- Case Western Reserve University
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Texas Children's Hospital
-
-
Virginia
-
Richmond, Virginia, Forente stater, 23298
- Virginia Commonwealth University
-
-
Washington
-
Seattle, Washington, Forente stater, 98195
- University of Washington
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
8 år til 17 år (Barn)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
- Age 8-17 years at first screening visit
- Histologic evidence of Nonalcoholic Fatty Liver Disease (NAFLD) - biopsy cannot be older than 6 months as of randomization
- ALT level >60 U/L at time of screening and on one previous occasion determined at least one month but no greater than 6 months prior to screening ALT
- Consent
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: 3
Matching placebo
|
Twice daily
|
|
Aktiv komparator: 1
Metformin, 500 mg, twice daily
|
500 mg, twice daily
|
|
Aktiv komparator: 2
Vitamin E, 400 IU, twice daily
|
400 IU, twice daily
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Sustained Reduction in Alanine Aminotransferase (ALT) to Either 50% of Baseline Value or < 40 IU/L
Tidsramme: baseline and 96 weeks
|
The primary outcome was sustained reduction in ALT level, defined as 50% or less of the baseline level or 40 IU/L or less at each visit from 48 to 96 weeks of treatment.
|
baseline and 96 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Serum Aspartate Aminotransferase (AST)
Tidsramme: baseline and 96 weeks
|
baseline and 96 weeks
|
|
|
Change in Nonalcoholic Fatty Liver Disease (NAFLD) Score (Histologic Feature Scores Determined by Standardized Scoring of Liver Biopsies) From Baseline at 96 Weeks of Treatment
Tidsramme: baseline and 96 weeks
|
Histological activity was assessed using the NAFLD activity score on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (0-3), lobular inflammation (0-3), and hepatocellular ballooning (0-2).
|
baseline and 96 weeks
|
|
Number of Participants With Improvement in Liver Fibrosis Score
Tidsramme: baseline and 96 weeks
|
Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis.
This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score at 96 weeks compared to baseline, which indicates improvement in fibrosis.
|
baseline and 96 weeks
|
|
Number of Participants With Improvement in Steatosis Score
Tidsramme: baseline and 96 weeks
|
Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis.
This secondary outcome measure is the number of participants that experienced a decrease in steatosis score at 96 weeks compared to baseline, which indicates improvement in steatosis.
|
baseline and 96 weeks
|
|
Number of Participants With Improvement in Lobular Inflammation Score
Tidsramme: baseline and 96 weeks
|
Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation.
This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score at 96 weeks compared to baseline, which indicates improvement in lobular inflammation.
|
baseline and 96 weeks
|
|
Number of Participants With Improvement in Ballooning Degradation Score
Tidsramme: baseline and 96 weeks
|
Ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe ballooning.
This secondary outcome measure is the number of participants that experienced a decrease in ballooning score at 96 weeks compared to baseline, which indicates improvement in ballooning.
|
baseline and 96 weeks
|
|
Change in Body Mass Index
Tidsramme: baseline and 96 weeks
|
baseline and 96 weeks
|
|
|
Change in Serum Vitamin E Levels
Tidsramme: baseline and 96 weeks
|
Change in alpha-Tocopherol
|
baseline and 96 weeks
|
|
Change in Quality of Life (QOL) Scores- Physical Health
Tidsramme: baseline and 96 weeks
|
Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life.
|
baseline and 96 weeks
|
|
Change in QOL- Psychosocial Health
Tidsramme: baseline and 96 weeks
|
Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life.
|
baseline and 96 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Guerrerio AL, Colvin RM, Schwartz AK, Molleston JP, Murray KF, Diehl A, Mohan P, Schwimmer JB, Lavine JE, Torbenson MS, Scheimann AO. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr. 2012 Apr;95(4):892-900. doi: 10.3945/ajcn.111.020156. Epub 2012 Feb 15.
- Corey KE, Vuppalanchi R, Vos M, Kohli R, Molleston JP, Wilson L, Unalp-Arida A, Cummings OW, Lavine JE, Chalasani N; Nonalcoholic Steatohepatitis Clinical Research Network. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2015 Mar;60(3):360-7. doi: 10.1097/MPG.0000000000000584.
- Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Unalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011 Apr 27;305(16):1659-68. doi: 10.1001/jama.2011.520.
- Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM, Unalp A, Tonascia J; Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials. 2010 Jan;31(1):62-70. doi: 10.1016/j.cct.2009.09.001. Epub 2009 Sep 15.
Hjelpsomme linker
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. september 2005
Primær fullføring (Faktiske)
1. september 2009
Studiet fullført (Faktiske)
1. februar 2010
Datoer for studieregistrering
Først innsendt
1. juli 2003
Først innsendt som oppfylte QC-kriteriene
2. juli 2003
Først lagt ut (Anslag)
3. juli 2003
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
27. september 2012
Siste oppdatering sendt inn som oppfylte QC-kriteriene
27. august 2012
Sist bekreftet
1. august 2012
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NASH - PEDIATRICS (IND)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .